<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937154</url>
  </required_header>
  <id_info>
    <org_study_id>20170770</org_study_id>
    <nct_id>NCT03937154</nct_id>
  </id_info>
  <brief_title>Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer</brief_title>
  <official_title>A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving&#xD;
      chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the&#xD;
      ability to administer on-time, full-dose chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, randomized, placebo-controlled, multicenter, international study for the&#xD;
      treatment of CIT in adult subjects receiving chemotherapy for the treatment of NSCLC, ovarian&#xD;
      cancer, or breast cancer. Subjects must have a platelet count &lt; 75 x 10^9/L on day 1 of the&#xD;
      study. The study will consist of a screening period of up to 4 weeks, a treatment period long&#xD;
      enough to allow for assessment of 3 planned cycles of chemotherapy, a follow-up visit, and&#xD;
      long-term follow-up (LTFU). Given that subjects are required to have 3 remaining planned&#xD;
      cycles of chemotherapy, the chemotherapy cycles may be 3 or 4 weeks in duration, and the&#xD;
      investigational product dose adjustment guidelines allow for up to 12 weeks of dosing before&#xD;
      a subject is declared a non-responder, the majority of study subjects will receive&#xD;
      investigational product for a range of 10-22 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">March 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will consist of a screening period of up to 4 weeks, a treatment period long enough to allow for assessment of 3 planned cycles of chemotherapy, a follow-up visit, and LTFU. Given that subjects are required to have 3 remaining planned cycles of chemotherapy, the chemotherapy cycles may be 3 or 4 weeks in duration, and the investigational product dose adjustment guidelines allow for up to 12 weeks of dosing before a subject is declared a non-responder, the majority of study subjects will receive investigational product for a range of 10-22 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of either a chemotherapy dose delay or reduction</measure>
    <time_frame>48 days</time_frame>
    <description>No thrombocytopenia-induced modification of any myelosuppressive agent in the second and third cycles of the planned on-study chemotherapy regimen. Thrombocytopenia-induced modifications include chemotherapy dose reduction, delay, omission, or chemotherapy treatment discontinuation due to platelet counts below 100 x 109/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depth of Platelet Count</measure>
    <time_frame>48 days</time_frame>
    <description>the depth of the platelet count nadir from the start of the first on-study chemotherapy cycle through the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First platelet response</measure>
    <time_frame>7 days</time_frame>
    <description>The time to first platelet response, defined by platelet count ≥ 100 x 109/L in the absence of platelet transfusions during the preceding 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the duration-adjusted event rate of ≥ grade 2 bleeding events</measure>
    <time_frame>48 days</time_frame>
    <description>the duration-adjusted event rate of ≥ grade 2 bleeding events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 Year</time_frame>
    <description>1-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at leat 1 incidence of platelet transfusion</measure>
    <time_frame>48 days</time_frame>
    <description>platelet transfusion(s) during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients achieving platelet count &gt;= 100 x 10 9/L</measure>
    <time_frame>7 days</time_frame>
    <description>7 days after 3rd dose of IP with no transfusions in preceding 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The subject incidence of adverse events</measure>
    <time_frame>36 months</time_frame>
    <description>Through end of study, up to 36 months. It will be counted in as an adverse event: any treatment - emergent adverse events, fatal adverse events, serious adverse events, or clinically significant changes in laboratory values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop anti-romiplostim antibodies</measure>
    <time_frame>36 Months</time_frame>
    <description>Through end of study up to 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop anti-TPO antibodies</measure>
    <time_frame>36 months</time_frame>
    <description>Through end of study, up to 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who experience myelodysplastic syndromes</measure>
    <time_frame>36 months</time_frame>
    <description>Through end of study, up to 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who experience secondary malignancies</measure>
    <time_frame>36 months</time_frame>
    <description>Through end of study, up to 36 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Chemotherapy-induced Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Romiplostim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romiplostim</intervention_name>
    <description>This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer</description>
    <arm_group_label>Romiplostim</arm_group_label>
    <other_name>Nplate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided informed consent prior to initiation of any study-specific&#xD;
             activities/procedures or subject's legally acceptable representative has provided&#xD;
             informed consent prior to any study-specific activities/procedures being initiated&#xD;
             when the subject has any kind of condition that, in the opinion of the investigator,&#xD;
             may compromise the ability of the subject to give written informed consent.&#xD;
&#xD;
          -  Males or females greater than or equal to 18 years of age at signing of the informed&#xD;
             consent.&#xD;
&#xD;
          -  Documented active stage I, II, III or IV locally advanced or metastatic NSCLC, breast&#xD;
             cancer, or ovarian cancer, or any stage recurrent disease. Patients with documented&#xD;
             locally advanced (stage III) NSCLC should not be amenable to definitive treatment with&#xD;
             chemoradiation and/or surgery.&#xD;
&#xD;
          -  Subjects must be receiving cancer treatment with 21- or 28-day cycles, using one of&#xD;
             the following carboplatinum-based combination chemotherapy regimens:&#xD;
             carboplatin/gemcitabine based, carboplatin/pemetrexed based, carboplatin/liposomal&#xD;
             doxorubicin based or carboplatin/taxane based (which includes either paclitaxel,&#xD;
             nab-paclitaxel, or docetaxel). Use of combination regimens with one of the above&#xD;
             carboplatinum-based regimens is permitted with (1) anti-angiogenic agents (such as&#xD;
             bevacizumab); (2) targeted therapy (such as anti-epidermal growth factor agents or&#xD;
             anti- human epidermal growth factor receptor 2) or (3) immune checkpoint inhibitors.&#xD;
             Cycle duration is based on intervals between day 1 of chemotherapy cycles (overlapping&#xD;
             with carboplatin intervals) every 21 or 28 days.&#xD;
&#xD;
          -  Subjects must have a platelet count less than 75 x 10 9/L on day 1 of the study.&#xD;
&#xD;
          -  Subjects must be at least 21 or 28 days removed from the start of the chemotherapy&#xD;
             cycle immediately prior to study day 1 if receiving a 21-day or 28-day cycle&#xD;
             chemotherapy regimen, respectively.&#xD;
&#xD;
          -  Subjects must have at least 3 remaining planned cycles of chemotherapy at study&#xD;
             enrollment.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute lymphoblastic leukemia.&#xD;
&#xD;
          -  Acute myeloid leukemia.&#xD;
&#xD;
          -  Any myeloid malignancy.&#xD;
&#xD;
          -  Myelodysplastic syndrome. Baseline bone marrow biopsy is not required to rule out MDS.&#xD;
             However, if a bone marrow biopsy and cytogenetics were performed as part of diagnostic&#xD;
             or staging work-up, these results will be collected to confirm.&#xD;
&#xD;
          -  Myeloproliferative disease.&#xD;
&#xD;
          -  Multiple myeloma.&#xD;
&#xD;
          -  Within 4 months prior to enrollment, any history of active congestive heart failure&#xD;
             (New York Heart Association [NYHA] Class III to IV), symptomatic ischemia,&#xD;
             uncontrolled arrhythmias, clinically significant electrocardiogram (ECG)&#xD;
             abnormalities, screening ECG with corrected QT (QTc) interval of greater than 470&#xD;
             msec, pericardial disease, or myocardial infarction.&#xD;
&#xD;
          -  Major surgery less than or equal to 28 days or minor surgery less than or equal to 3&#xD;
             days prior to enrollment.&#xD;
&#xD;
          -  New or uncontrolled venous thromboembolism or thrombotic events within 3 months prior&#xD;
             to screening. To be eligible, subjects must have received at least 14 days of&#xD;
             anticoagulation for a new thrombotic event and considered to be stable and suitable&#xD;
             for continued therapeutic anticoagulation during trial participation.&#xD;
&#xD;
          -  History of arterial thrombotic events (eg, myocardial ischemia, transient ischemic&#xD;
             attack, or stroke) within 6 months prior to screening.&#xD;
&#xD;
          -  Evidence of active infection within 2 weeks prior to the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Known human immunodeficiency virus infection. Subjects without a documented diagnosis&#xD;
             in their medical history will require a central. laboratory assessment at screening.&#xD;
&#xD;
          -  Known active of chronic hepatitis C or hepatitis B infection. Subjects without a&#xD;
             documented diagnosis in their medical history will require a central laboratory&#xD;
             assessment at screening. Hepatitis B and C infection is based on the following&#xD;
             results:&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen (HBsAg) (indicative of chronic hepatitis B or&#xD;
             recent acute hepatitis B).&#xD;
&#xD;
          -  Negative HBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA by&#xD;
             polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA&#xD;
             suggests occult hepatitis B.&#xD;
&#xD;
          -  Positive hepatitis C virus antibody: hepatitis C virus RNA by PCR is necessary.&#xD;
             Detectable hepatitis C virus RNA suggests chronic hepatitis C.&#xD;
&#xD;
          -  In addition to the conditions listed in exclusion criteria 201 through 206, secondary&#xD;
             malignancy within the past 5 years except:&#xD;
&#xD;
          -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of&#xD;
             disease.&#xD;
&#xD;
          -  Adequately treated cervical carcinoma in situ without evidence of disease.&#xD;
&#xD;
          -  Adequately treated breast ductal carcinoma in situ without evidence of disease.&#xD;
&#xD;
          -  Prostatic intraepithelial neoplasia without evidence of prostate cancer.&#xD;
&#xD;
          -  Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.&#xD;
&#xD;
          -  Malignancy treated with curative intent and with no known active disease present for&#xD;
             greater than or equal to 3 years before enrollment and felt to be at low risk for&#xD;
             recurrence by the treating physician (excluding malignancies listed in exclusion&#xD;
             criteria 201 - 206).&#xD;
&#xD;
          -  Thrombocytopenia due to another etiology other than CIT (eg, chronic liver disease,&#xD;
             prior history of immune thrombocytopenia purpura).&#xD;
&#xD;
          -  Any combined modality regimen containing radiation therapy or surgery occurring&#xD;
             concomitantly with neo-adjuvant chemotherapy or where radiation therapy is planned&#xD;
             before the planned chemotherapy.&#xD;
&#xD;
        Prior/Concomitant Therapy:&#xD;
&#xD;
        - Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and&#xD;
        development factor, eltrombopag, recombinant human TPO, any other TPO receptor agonist, or&#xD;
        any investigational platelet producing agent.&#xD;
&#xD;
        Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
        - Currently receiving treatment in another investigational device or drug study, or less&#xD;
        than 28 days since ending treatment on another investigational device or drug study(ies).&#xD;
        Other investigational procedures while participating in this study are excluded.&#xD;
&#xD;
        Diagnostic Assessments&#xD;
&#xD;
          -  Anemia (hemoglobin less than 8 g/dL) on the day of initiation of investigational&#xD;
             product as assessed by local labs. Use of red cell transfusions and erythropoietic&#xD;
             stimulating agents is permitted throughout the study as per institutional guidelines.&#xD;
&#xD;
          -  Neutropenia (absolute neutrophil count less than 1 x 10 9/L) on the day of initiation&#xD;
             of investigational product as assessed by local labs. Use of granulocyte-colony&#xD;
             stimulating factor is permitted throughout the study as per institutional guidelines.&#xD;
&#xD;
          -  Abnormal renal function with creatinine clearance less than 30 mL/min using the&#xD;
             Cockcroft-Gault estimated creatinine clearance as assessed by central laboratory&#xD;
             during screening.&#xD;
&#xD;
          -  Abnormal liver function (total bilirubin greater than 3X ULN; alanine aminotransferase&#xD;
             [ALT] or aspartate aminotransferase [AST] greater than 3X ULN for subjects without&#xD;
             liver metastases or greater than or equal to 5X ULN for subjects with liver&#xD;
             metastases) as assessed by central laboratory during screening.&#xD;
&#xD;
        Other Exclusions&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed&#xD;
             during treatment and for an additional 7 months after treatment (and chemotherapy)&#xD;
             discontinuation (females of childbearing potential should only be included after a&#xD;
             confirmed menstrual period and a negative highly sensitive urine or serum pregnancy&#xD;
             test.)&#xD;
&#xD;
          -  Females of childbearing potential unwilling to use a highly effective method of&#xD;
             contraception during treatment and for an additional 7 months after treatment (and&#xD;
             chemotherapy) discontinuation. Refer to Appendix 5 for additional contraceptive&#xD;
             information.&#xD;
&#xD;
          -  Males unwilling to use contraception* (male condom or sexual abstinence) or their&#xD;
             female partner(s) of childbearing potential who are unwilling to use a highly&#xD;
             effective method of contraception during treatment (and chemotherapy) and for an&#xD;
             additional 7 months after treatment (and chemotherapy) discontinuation. *If the male's&#xD;
             sole partner is of non-childbearing potential, he is not required to use additional&#xD;
             forms of contraception during the study.&#xD;
&#xD;
          -  Subject has known sensitivity to any of the products to be administered during dosing.&#xD;
&#xD;
          -  Subject likely to not be available to complete all protocol-required study visits or&#xD;
             procedures, and/or to comply with all required study procedures (eg, COAs) to the best&#xD;
             of the subject and investigator's knowledge.&#xD;
&#xD;
          -  History or evidence of any other clinically significant disorder, condition or disease&#xD;
             (with the exception of those outlined above) that, in the opinion of the investigator&#xD;
             or Amgen physician, if consulted, would pose a risk to subject safety or interfere&#xD;
             with the study evaluation, procedures or completion.&#xD;
&#xD;
          -  Male subjects with a pregnant partner who are unwilling to practice abstinence or use&#xD;
             a condom during treatment (and chemotherapy) and for an additional 7 months after&#xD;
             treatment (and chemotherapy) discontinuation.&#xD;
&#xD;
          -  Male subjects unwilling to abstain from donating sperm during treatment (and&#xD;
             chemotherapy) and for an additional 7 months after treatment (and chemotherapy)&#xD;
             discontinuation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Bernards Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center Inc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California at Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado West Healthcare System dba Grand Valley Oncology</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Florida Hematology and Oncology Centers PA</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christus Saint Frances Cabrini Hospital</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Highland Cancer Treatment Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland, PA</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic Hematology/Oncology</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Sparta</city>
        <state>New Jersey</state>
        <zip>07871</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Broome Oncology LLC</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Oncologico Cordoba</name>
      <address>
        <city>Cordoba</city>
        <state>Córdoba</state>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Austral</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Distrito Federal</state>
        <zip>C1019ABS</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clínicas Clínica Viedma</name>
      <address>
        <city>Viedma</city>
        <state>Río Negro</state>
        <zip>8500</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia do Parana</name>
      <address>
        <city>Curitba</city>
        <state>Paraná</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vencer e Oncoclinica</name>
      <address>
        <city>Teresina</city>
        <state>Piauí</state>
        <zip>64049-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa da Serra Gaucha - Cepesg</name>
      <address>
        <city>Caxias do Sul</city>
        <state>Rio Grande Do Sul</state>
        <zip>95020-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Loema Instituto de Pesquisa Clinica &amp; Consultores Ltda</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13010-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casa de Saude Santa Marcelina</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>08270-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Serdika EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Oncology EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlandi Oncologia</name>
      <address>
        <city>Santiago</city>
        <zip>7500713</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncomedica Imat</name>
      <address>
        <city>Monteria</city>
        <state>Córdoba</state>
        <zip>230002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agios Savvas Anticancer Hospital</name>
      <address>
        <city>Athens</city>
        <zip>115 22</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Dunant Hospital Center</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sotiria General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion</name>
      <address>
        <city>Heraklion - Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iatriko Diavalkaniko Thessalonikis</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Tudogyogyintezet</name>
      <address>
        <city>Farkasgyepu</city>
        <zip>8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tudogyogyintezet Torokbalint</name>
      <address>
        <city>Torokbalint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncotech</name>
      <address>
        <city>La Paz</city>
        <state>Baja California Sur</state>
        <zip>23040</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion e Investigacion Cardiovascular del Potosi Sc</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis Potosí</state>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Nacional Siglo XXI</name>
      <address>
        <city>Mexico</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oaxaca Site Management Organization SC</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Goyeneche</name>
      <address>
        <city>Arequipa</city>
        <zip>04001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncosalud</name>
      <address>
        <city>Lima</city>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Powiatowe Centrum Zdrowia w Brzezinach Sp Z o o</name>
      <address>
        <city>Brzeziny</city>
        <zip>95-060</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitario de Lisboa Norte EPE - Hospital Pulido Valente</name>
      <address>
        <city>Lisboa</city>
        <zip>1769-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano</name>
      <address>
        <city>Matosinhos</city>
        <zip>4464-513</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitario do Porto EPE - Hospital de Santo Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Sao Joao, EPE</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic, Prof Dr Alexandru Trestioreanu</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic, Prof Dr Alexandru Trestioreanu</name>
      <address>
        <city>Bucharest</city>
        <zip>022338</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Coltea</name>
      <address>
        <city>Bucharest</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Oncologie Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Municipal Ploiesti</name>
      <address>
        <city>Ploiesti</city>
        <zip>100337</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SC Oncomed SRL</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBHI of Arkhangelsk region Arkhangelsk clinical oncology dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Autonomic SHI Republican clinical oncology dispensary of MoH of the Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medsi Group</name>
      <address>
        <city>Moscow Region</city>
        <zip>143442</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Goroda Moskvi City Clinical Hospital 1</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical hospital 2, Group of companies medsi</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Tonus</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omsk Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State budget institution of public health Pyatigorsk oncology dispensary</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>State Institution of Public Health</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Institution of Public Health Oncology Dispensary 2 of Public Health Krasnodar Region</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>State Institution of Public Health Tambov Regional Oncology Dispensary</name>
      <address>
        <city>Tambov</city>
        <zip>390013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria Nai</name>
      <address>
        <city>Ourense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Doktor Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saglik Bilimleri University Ankara Ataturk Chest Diseases and Chest Surgery Training and Research Ho</name>
      <address>
        <city>Ankara</city>
        <zip>06280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pamukkale Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Denizli</city>
        <zip>20070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pendik Egitim Arastirma Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Izmir</city>
        <zip>35150</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Park Izmir Hastanesi</name>
      <address>
        <city>Izmir</city>
        <zip>35575</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kocaeli Universitesi Arastirma ve Uygulama Hastanesi</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inonu Universitesi Turgut Ozal Tip Merkezi</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Namik Kemal Universitesi Hastanesi</name>
      <address>
        <city>Tekirdag</city>
        <zip>59100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Institution Chernivtsi Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Transcarpathian Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vinnytsya Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy-induced thrombocytopenia</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

